News by National Association of Boards of Pharmacy. & Massachusetts. Board of Registration in Pharmacy.
MA Vol. 1, No. 1 Page 1
Newsletter Returns . . . by Popular 
Demand!
The Massachusetts Board of Registration in Pharmacy 
welcomes you to the first issue of its Newsletter. For those of 
you with extensive pharmacy experience, you may remember 
receiving this as a printed, mailed version in the past.
The Board hopes to promote compliance of pharmacy 
law and best practices by educating its licensees on both 
state and national pharmacy news topics. You can receive 
this Newsletter every quarter electronically by using the 
subscribe link on the National Association of Boards of 
Pharmacy® website at www.nabp.pharmacy/boards-of-
pharmacy/massachusetts or asking to be added to the Board’s 
distribution list by emailing Pharmacy.Admin@MassMail 
.State.MA.US. The distribution list periodically sends out 
information related to new Board advisories, policies, and 
regulations and is a great way to stay up to date on Mas-
sachusetts pharmacy practice. The Board welcomes your 
suggestions for any topics you would like to see addressed. 
Gabapentin and MassPAT
The Massachusetts Prescription Awareness Tool 
(MassPAT) is an online tool utilized by authorized pro-
viders that supports safe prescribing and dispensing of 
Schedule II-V controlled substances (CS). It is part of 
the Massachusetts Prescription Monitoring Program and 
requires pharmacies to report prescribing and dispensing 
information for all drugs in Schedules II-V and those 
drugs in Schedule VI that have been designated as “ad-
ditional drugs.” This information is then used to provide 
more complete information to prescribers, dispensers, and 
regulatory agencies in order to identify prescribing and 
dispensing trends, detect drug abuse and diversion, and 
facilitate communication between health care providers 
based on a patient’s prescription fill history. 
Because of its abuse potential, gabapentin has been 
classified as an “additional drug” and must be reported 
to MassPAT as of August 1, 2017. 
More information about MassPAT and its use may be 
found at www.mass.gov/dph/dcp/pmp.
Out-of-State Prescriptions
Schedule III-VI prescriptions can be issued by any au-
thorized practitioner from any state but must be filled within 
30 days of the date written. Pharmacists must request and 
record that a written prescription be forwarded within seven 
days for any out-of-state Schedule III-V oral prescriptions. 
Nonnarcotic Schedule II prescriptions can only be 
issued by authorized physicians (no other practitioners) 
from any state. These prescriptions must be filled within 
five days of the date written. 
Finally, narcotic Schedule II prescriptions can only be 
issued by authorized physicians (no other practitioners) 
who are properly licensed and registered in Connecti-
cut, Maine, Massachusetts, New Hampshire, New York, 
Rhode Island, or Vermont. These prescriptions must be 
filled within five days of the date written. 
For more information, visit https://malegislature.gov/
Laws/GeneralLaws/PartI/TitleXV/Chapter94C/Section18.
Regulatory Update
The Board continues its review of existing regulations, 
as well as drafting new ones for compounding, hazardous 
drugs, and fines. 
A public hearing for regulations 247 Code of Massa-
chusetts Regulations 5.00, 6.00, 9.00, 12.00, 15.00, and 
20.00 was held on June 29, 2017. After all comments are 
collated, they will be presented to the Board members for 
possible inclusion and final approval. 
To view comments that have been submitted, visit 
www.mass.gov/eohhs/gov/departments/dph/programs/
hcq/dhpl/pharmacy/public-hearings.html.
Vaccination Update
Regulations have been recently revised to allow quali-
fied pharmacists and pharmacy interns to administer 
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well-known and repetitive dispensing errors. Pharmacies should 
seek out medication safety information and use it proactively to pre-
vent medication errors. At the same time, safety issues recognized 
internally and/or reported by patients should be documented and 
analyzed, with a process to determine the best strategies to prevent 
future problems and methods to ensure implementation. An annual 
survey to assess consumer perceptions of the quality of pharma-
ceutical products and professional services could supply additional 
information upon which to base improvement strategies. For more 
information on CQI programs, visit Section 7 of Model Rules for 
the Practice of Pharmacy in The Model State Pharmacy Act and 
Model Rules of the National Association of Boards of Pharmacy.
Informational tools like the ISMP Medication Safety 
Alert! publication, or ISMP’s Quarterly Action Agenda, which is 
a readily available list of medication problems compiled from the 
nation’s reporting programs, can be a backbone of any CQI effort. 
The very purpose of the ISMP Medication Errors Reporting Pro-
gram  – indeed the purpose of any type of safety reporting program 
and the expert recommendations that stem from it – is to guide the 
implementation of quality improvement initiatives by practitioners 
and organizations. 
It is important that certain information from the CQI proceedings 
and records of review be protected from discovery. Patient safety 
organizations (PSO) are organizations that share the goal of improv-
ing the quality and safety of health care delivery. Patient Safety 
Work Product (PSWP) is the information protected by the privilege 
and confidentiality protections of the Patient Safety Act and Patient 
Safety Rule. PSOs serve as independent, external experts who 
can collect, analyze, and aggregate PSWP locally, regionally, and 
nationally to develop insights into the underlying causes of patient 
safety events, thus improving quality by identifying and reducing 
the risks and hazards associated with patient care. Communications 
with PSOs are protected to allay fears of increased risk of liability 
because of collection and analysis of patient safety events.
For more information on PSOs, visit https://www.pso.ahrq 
.gov/faq.
NCPDP Releases Guide to Ensure Patients 
Get Their Medications During a Disaster
The National Council for Prescription Drug Programs (NCPDP) 
released the NCPDP Emergency Preparedness Information guide 
to assist pharmacists and other health care providers during a 
declared emergency. Prepared by the NCPDP Emergency Pre-
paredness Committee, the guide provides resource information 
for eligibility and claims processing affecting displaced individu-
als. The guide is available at www.ncpdp.org/NCPDP/media/pdf/
NCPDPEmergencyPreparednessInformation_v1_4.pdf. Additional 
information for pharmacists about emergency preparedness is 
available on the NCPDP website at www.ncpdp.org/Resources/
Emergency-Preparedness. 
FDA Warns of Illnesses and Deaths in Pets 
Exposed to Fluorouracil
Food and Drug Administration (FDA) is alerting pharmacists 
that patients’ pets are at risk of illness and death when exposed 
to the topical cancer medication fluorouracil cream USP 5% 
(5-FU) that is intended for use in people. Fluorouracil may 
also be marketed under the brand names Carac®, Efudex®, and 
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WHO Launches Global Patient Safety 
Challenge on Medication Safety
To reduce severe, avoidable medication-associated harm in 
all countries by 50% over the next five years, the World Health 
Organization (WHO) has launched a worldwide initiative, the 
Global Patient Safety Challenge on Medication Safety. Medication 
errors cause at least one death every day and injure approximately 
1.3 million people every year in the United States. In addition, low- 
and middle-income countries are estimated to have similar rates 
of medication-related adverse events as high-income countries.
The Global Patient Safety Challenge on Medication Safety aims 
to make improvements in each stage of the medication use process 
including prescribing, dispensing, administering, monitoring, and 
use. WHO intends to provide guidance and develop strategies, in 
addition to plans and tools to ensure that the medication process 
has the safety of patients at its core in all health care facilities. 
Previous WHO Global Safety Challenges have included the 
Clean Care is Safer Care challenge on hand hygiene in 2005 
and the Safe Surgery Saves Lives challenge in 2008. Additional 
information is available in the WHO press release available at 
http://who.int/mediacentre/news/releases/2017/medication-related-
errors/en.
Continuous Quality Improvement and Patient 
Safety Organizations 
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency and 
federally certified patient safety organization 
that analyzes medication errors, near misses, and potentially 
hazardous conditions as reported by pharmacists and other 
practitioners. ISMP then makes appropriate contacts with 
companies and regulators, gathers expert opinion about prevention 
measures, and publishes its recommendations. To read about the risk 
reduction strategies that you can put into practice today, subscribe 
to ISMP Medication Safety Alert!® Community/Ambulatory Care 
Edition by visiting www.ismp.org. ISMP provides legal protection 
and confidentiality for submitted patient safety data and error 
reports. Help others by reporting actual and potential medication 
errors to the ISMP National Medication Errors Reporting Program 
Report online at www.ismp.org. Email: ismpinfo@ismp.org.
Data from the ISMP Medication Errors Reporting Program 
reveals that medication-related problems are repetitive in nature. 
An incident of misuse in one setting is likely to repeat itself in 
another. Most importantly, the system changes that are necessary 
to prevent errors are similar, and a growing body of literature is 
available to guide these efforts. Tragically, too many organizations 
and individual providers do not believe similar incidents could hap-
pen to them. They fail to use information about errors occurring 
elsewhere as a roadmap for improvement in their own organization 
or practice. It is not until a serious error hits home that aggressive 
prevention efforts are implemented. With so much evidence-based 
information about error prevention at hand, there is little excuse 
for reacting to errors after they happen instead of preventing them. 
The development and implementation of continuous quality 
improvement (CQI) efforts should be the highest priority in all 
pharmacies. Such efforts must be aimed specifically at preventing 
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Fluoroplex®. Very small amounts could be dangerous to household 
pets; thus, patients should use care when applying and storing the 
medication. FDA has received reports of five dogs that became 
ill and died after accidentally ingesting the topical cream, notes 
a Center for Veterinary Medicine Update available at www.fda 
.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm537434.htm. 
Although FDA has not received any reports involving cats to 
date, cats are also expected to be extremely sensitive to fluorouracil 
cream. For instance, if an owner applies fluorouracil cream to an 
afflicted area and touches his or her cat, the cat may accidentally 
ingest the medication when grooming itself and suffer adverse 
events. 
FDA advises that pharmacists who fill these prescriptions 
should advise patients with pets to prevent exposing their pet to 
the medication. Adverse events may be reported to FDA using 
the Form FDA 1932a, which may be obtained at www.fda.gov/
AnimalVeterinary/SafetyHealth/ReportaProblem/ucm055305.htm. 
FDA Revises Final Guidance Documents on 
Bulk Drug Substances Used in Compounding
In January 2017, FDA issued revised versions of two final 
guidance documents regarding the use of bulk drug substances in 
compounding.
 ♦ Interim Policy on Compounding Using Bulk Drug Sub-
stances Under Section 503A of the Federal Food, Drug, and 
Cosmetic Act
 ♦ Interim Policy on Compounding Using Bulk Drug Sub-
stances Under Section 503B of the Federal Food, Drug, and 
Cosmetic Act 
FDA clarified that the policies described in the guidances do not 
apply to inactive ingredients. Inactive ingredients are not included 
in the definition of a “bulk drug substance” and can be used in 
compounding without appearing on the bulk drug substances lists 
developed under sections 503A or 503B of the Federal Food, Drug, 
and Cosmetic Act, if all applicable conditions are met. 
As indicated on its website at www.fda.gov/Drugs/DrugSafety/
ucm502075.htm, FDA will also provide regular updates to the cat-
egories of bulk drug substances described in the guidances. FDA 
previously stated that it would not evaluate new nominations for 
placement in one of the three categories until after it completed its 
review of substances already nominated with adequate supporting 
information. 
Now, the guidances state that FDA will determine after submis-
sions are received whether new nominations, including renomina-
tions of substances with additional supporting information, have 
sufficient information for FDA to review them. After making 
that determination, FDA will place nominated substances in the 
appropriate category on FDA’s website. FDA intends to update 
the categories with any new nominations the first business day of 
each month. This revised policy will further minimize unnecessary 
disruptions to patient treatment while FDA develops the lists of 
bulk drug substances for use in compounding. 
The guidances are available online at www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guid-
ances/UCM469120.pdf and www.fda.gov/downloads/Drugs/ 
GuidanceComplianceRegulatoryInformation/Guidances/
UCM469122.pdf. 
APhA Resource Guide Applies JCPP 
Pharmacists’ Patient Care Process to 
Immunization Services
The American Pharmacists Association (APhA) published 
a resource guide that applies the Joint Commission of Phar-
macy Practitioners (JCPP) Pharmacists’ Patient Care Process to 
pharmacy-based immunization services. The components of the 
Pharmacists’ Patient Care Process to collect, assess, plan, imple-
ment, and follow-up should be implemented as routine practice 
along with the National Vaccine Advisory Committee Standards 
for Adult Immunization Practice, as noted in the resource guide, 
Applying the Pharmacists’ Patient Care Process to Immuniza-
tion Services. “[P]harmacists and other vaccine providers need to 
strive to constantly improve collaboration, communication, and 
documentation,” indicates the APhA guide. For more information, 
visit the APhA Immunization Center at www.pharmacist.com/
immunization-center. 
CPE Training on Older Adult Fall Prevention 
Available Online
Developed in collaboration with the Centers for Disease Con-
trol and Prevention (CDC) and the APhA, the Stopping Elderly 
Accidents, Deaths, and Injuries (STEADI) initiative is offering 
continuing pharmacy education (CPE) training for pharmacists 
to prevent falls in adults 65 and older. The training will provide 
strategies to help pharmacists screen older adults for fall risk, 
conduct medication review and management, and offer patient 
education. To participate in the free online training, “STEADI: The 
Pharmacist’s Role in Older Adult Fall Prevention,” visit the CDC 
website at www.cdc.gov/steadi/training.html for more information. 
New FDA Drug Info Rounds Training Video 
Addresses the Combat Methamphetamine 
Epidemic Act
Drug Info Rounds, a series of online videos by FDA, provides 
important and timely drug information to practicing clinical and 
community pharmacists so they can help patients make bet-
ter decisions. In the latest Drug Info Rounds video, “Combat 
Methamphetamine Epidemic Act,” pharmacists discuss the legal 
requirements for the sale of over-the-counter drug products that 
contain pseudoephedrine. Drug Info Rounds was developed with 
contributions from pharmacists in FDA’s Center for Drug Evalu-
ation and Research (CDER), Office of Communications, Division 
of Drug Information. All Drug Info Rounds videos can be viewed 
on the FDA website at www.fda.gov/Drugs/ResourcesForYou/
HealthProfessionals/ucm211957.htm.
FDA Presents Series of CE Webinars for 
Students and Clinicians
FDA’s Division of Drug Information in the CDER presents 
a series of continuing education (CE) webinars targeted toward 
students and health care providers who wish to learn more about 
FDA and drug regulation. The webinars are presented by FDA 
staff and allow participants to interact with staff. Previous webinar 
topics have included an overview of FDA’s role in medication er-
ror prevention and prescription drug labeling. The webinars and 
presentation slides can be accessed on FDA’s website at www.fda 
.gov/DDIWebinars.
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certain vaccines to individuals nine years of age and 
older. Only vaccines included in the latest immunization 
schedule as approved by the Advisory Committee on 
Immunization Practices (ACIP) of the Centers for Disease 
Control and Prevention are permitted to be administered.
Of note, since the ACIP does not currently recommend 
the zoster vaccine (ie, Zostavax®) for adults ages 50 
through 59, pharmacists and pharmacy interns are not per-
mitted to administer the zoster vaccine to this age group. 
Revised regulations may be viewed at www.mass.gov/
courts/docs/lawlib/104-105cmr/105cmr700.pdf. The 
Board’s vaccine policy may be viewed at www.mass 
.gov/eohhs/gov/departments/dph/programs/hcq/dhpl/
pharmacy/pharmacy-regs/policies.
Pharmacy Intern Supervision
Supervising a pharmacy intern can be a rewarding and 
educational process for both the preceptor and student. 
Bear in mind that a pharmacist preceptor may not directly 
supervise more than two pharmacy interns at one time 
during dispensing functions or patient care activities. 
There are settings where a pharmacy intern may work 
in an office or similar setting without patient or provider 
contact, doing research or working on projects; in these 
situations, no direct supervision is required. 
It is important to note that a licensed pharmacist must 
be present at all times when any intern participates in 
patient or practitioner consultations or recommendations, 
or perform any other duty in which an intern’s error could 
have a negative impact on patient safety. 
The Board encourages its licensees to read the advi-
sory addressing supervisory ratios, among other topics, 
on the Massachusetts Executive Office of Health and 
Human Services website at www.mass.gov/eohhs/gov/
departments/dph/programs/hcq/dhpl/pharmacy/alerts/
pharmacy-board-advisories.html.
Did You Know?
♦ You can email the Board with practice inquiries at
Pharmacy.Admin@MassMail.State.MA.US.
♦ In order to participate in a research study, whether
with commercially available approved drugs or not,
a study-specific CS registration is required from the
Massachusetts Drug Control Program.
♦ Pharmacies may not provide “stock supply” medi-
cations to any office or facility. This includes such
products as vaccines and naloxone.
Technician Training
In order to standardize technician training throughout 
the Commonwealth of Massachusetts, the Board has ad-
opted new guidelines for approval. Policy 2017-01 details 
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the requirements for obtaining approval for pharmacy 
technician exams and training programs. For details, visit 
www.mass.gov/eohhs/docs/dph/quality/boards/pharmacy/
alerts/policy-2017-01.pdf.
Reporting Lost Controlled Substances
The number of CS a pharmacy handles in one day can 
be astounding. If at some point a loss of CS occurs, it is 
important to report it properly. Only those pharmacies 
that hold a license with the Board are required to report, 
in the manner outlined below. 
Within one business day of a suspected reportable loss, 
a pharmacy must report Section A of the Report of Loss 
of Controlled Substances (RLCS) form to the Board. 
Within 30 days of submission of Section A, the pharmacy 
must submit Section B of the RLCS form, including 
investigation results, police reports (if applicable), and 
any other related documentation. The RLCS form can 
be downloaded online at www.mass.gov/eohhs/docs/dph/
quality/boards/pharmacy/borp-report-loss-controlled-
substance.pdf.
Pharmacies are still required to submit a Drug Enforce-
ment Administration (DEA) Form 106 to DEA, state 
police, and local police, as well as to the Board if there 
is a significant theft or loss of federally controlled sub-
stances. Please review DEA’s definition of “significant 
loss” at https://www.deadiversion.usdoj.gov/fed_regs/
rules/2005/fr0812.htm.
The Board approved this procedure in late 2016 to allow 
pharmacies enough time to conduct a thorough internal 
investigation. In many cases, the increased investigative 
time proved helpful in loss reconciliation. 
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